Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
Citations
671 citations
484 citations
Cites background from "Randomized, Double-Blind, Phase II ..."
...We have previously shown that PARP is overexpressed in SCLC tumors (14) and that PARP inhibition has activity in preclinical models (15, 25), and recent clinical trials have demonstrated clinical benefit from PARP inhibitors in some patients with SCLC (16, 19)....
[...]
294 citations
Cites result from "Randomized, Double-Blind, Phase II ..."
...Veliparib combined with temozolomide showed improved objective response rate in SCLC patients (Pietanza et al. 2018), while talazoparib alone or in combination with temozolomide yielded promising results in PDXmodels of SCLC (Lok et al. 2017; Laird et al. 2018)....
[...]
290 citations
271 citations
Cites background from "Randomized, Double-Blind, Phase II ..."
...Overall, the SLFN11 expression level and its degree of methylation can be used as predictive biomarkers of the therapeutic effects of chemotherapy drugs [100]....
[...]
References
20,760 citations
5,650 citations
Additional excerpts
...5 (31-84) 62 (35 -84) 63 (31-80) ECOG performance status, No....
[...]
4,244 citations
Additional excerpts
...5 (31-84) 62 (35 -84) 63 (31-80) ECOG performance status, No....
[...]
...(%) 1 70 (67) 34 (69) 36 (65) 2 34 (33) 15 (31) 19 (35) Cohort designation, No....
[...]
3,332 citations
Additional excerpts
...5 (31-84) 62 (35 -84) 63 (31-80) ECOG performance status, No....
[...]
1,694 citations